Anto Biosciences

Y Combinator Fall 2025 · Microbiology & synthetic biology · North America

What it sells

A Foundation Model for Microbial Communities.

Business model breakdown

Workflow: what inputs become what output?

Darwin model series predicts drug toxicity and efficacy across populations and optimizes molecules, with lab-in-the-loop validation.

Funding history and coverage

Round dateStageAmountInvestorsSource
—Y Combinator Fall 2025—Y Combinatorycombinator.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.

More startups in Microbiology & synthetic biology

  1. Microbiotica

    Develops precision microbiome medicines: defined live biotherapeutic products with known mechanisms of action, focused on immuno-oncology and inflammatory bowel disease.

  2. BioConsortia

    BioConsortia develops microbial biological inputs for crops in nitrogen fixation, biocontrol and biostimulants, designed primarily for seed application, using its microbe…

  3. K-Bio Gateway

    Develops 'diet probiotics' and green-bio materials (DH24).

    Seed · KRW 1.2B · 2026-09-21Microbiology & synthetic biologyKorea
  4. Generare

    Molecular data for drug development from microbial genomes.

  5. baCta

    Microorganisms as programmable factories for industrial ingredients.

  6. ZBiotics

    ZBiotics makes genetically engineered probiotics.

All startups in this market →